MGD024 vs Mipletamig
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 x CD3 · full Acute Myeloid Leukemia pipeline
MGD024
Developed by MacroGenics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT05362773 (registry estimate)
No aligned efficacy figure on record for this race.
Mipletamig
Developed by Aptevo Therapeutics
NCT03647800 · Phase 1 · status unknown
This is an open-label, single-arm, dose-escalation and dose-expansion study with no control group and no blinding, so it cannot demonstrate a treatment effect on its own. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
These results cover the monotherapy dose-escalation cohort only; combination-therapy expansion cohorts added later are not included. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2027 · NCT06634394 (registry estimate)
Reported efficacy
Part 1 - Dose Escalation: Maximum Tolerated Dose (during first 28 to 35 days of treatment); Part 2 - Dose Expansion: Safety (during first 28 to 35 days of treatment): MTD not reached at a weekly dose of 60 mcg; infusion-related reactions occurred in 28.3% of patients and cytokine release syndrome in 21.7% (severe CRS 8.7%); Eight of 34 (23.5%) evaluable relapsed AML patients showed favorable responses and 3 of 6 (50%) evaluable relapsed MDS patients had a marrow CR. (not_applicable)
Result source: NCT03647800
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | MGD024 | Mipletamig |
|---|---|---|
| OS, median | —Not reported | —Not reported |
| Complete remission | —Not reported | —Not reported |
| Event-free survival, median | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
OS, median
- MGD024
- —Not reported
- Mipletamig
- —Not reported
Complete remission
- MGD024
- —Not reported
- Mipletamig
- —Not reported
Event-free survival, median
- MGD024
- —Not reported
- Mipletamig
- —Not reported
Duration of response, median
- MGD024
- —Not reported
- Mipletamig
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
MGD024: no structured comparison results are available for Acute Myeloid Leukemia.
Mipletamig: no structured comparison results are available for Acute Myeloid Leukemia.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MGD024's landscape · Mipletamig's landscape